Q4 2011 Oxygen Biotherapeutics Inc Earnings Conference Call
Q1 2012 Oxygen Biotherapeutics Inc Earnings Conference Call
Oxygen Biotherapeutics General Annual Meeting
Oxygen Biotherapeutics Inc at Piper Jaffray Health Care Conference
Q2 2012 Oxygen Biotherapeutics Inc Earnings Conference Call
Third Quarter Form 10-Q Filing and Press Release
Q3 2012 Oxygen Biotherapeutics Inc Earnings Conference Call
OneMedForum 2012 Emerging Company Finance Conference
Q4 2012 Oxygen Biotherapeutics Inc Earnings Conference Call
Oxygen Biotherapeutics General Annual Meeting
Q1 2013 Oxygen Biotherapeutics, Inc. Earnings Conference Call
Q2 2013 Oxygen Biotherapeutics, Inc. Earnings Conference Call
Business Review and Update in Conjunction with Filing of Fiscal Year 2016 Second Quarter Financial Report
Business Review and Update in Conjunction with Filing of Fiscal Year 2016 First Quarter Financial Report
From:
Thursday, May 19, 2016 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Thursday, May 19, 2016 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
Business Review and Update in Conjunction with Filing of 10K Transition Financial Report
From:
Wednesday, March 16, 2016 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Wednesday, March 16, 2016 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
Cowen and Company 36th Annual Health Care Conference Presentation
From:
Monday, March 7, 2016 2:40 pm EST (1:40 pm CST, 12:40 pm MST, 11:40 am PST)
To:
Monday, March 7, 2016 3:40 pm EST (2:40 pm CST, 1:40 pm MST, 12:40 pm PST)
Duration: 1 Hour
Related Materials:
Corporate Overview (1.11 MB)
The LEERINK Partners 5th Annual Global Healthcare Conference
From:
Thursday, February 11, 2016 2:40 pm EST (1:40 pm CST, 12:40 pm MST, 11:40 am PST)
To:
Thursday, February 11, 2016 3:40 pm EST (2:40 pm CST, 1:40 pm MST, 12:40 pm PST)
Duration: 1 Hour
Related Materials:
TENX Overview - February 2016 Leerink (1.12 MB)
Ladenburg Thalmann 2015 Conference Presentation
Corporate Update and Discussion of First Quarter Fiscal Year 2016
From:
Monday, September 14, 2015 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Monday, September 14, 2015 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
2015 Wedbush PacGrow Healthcare Conference
From:
Wednesday, August 12, 2015 10:55 am EDT (9:55 am CDT, 8:55 am MDT, 7:55 am PDT)
To:
Wednesday, August 12, 2015 11:55 am EDT (10:55 am CDT, 9:55 am MDT, 8:55 am PDT)
Duration: 1 Hour
Business Review and Update in Conjunction with Filing of Fiscal Year 2015 Annual Report
From:
Thursday, July 16, 2015 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Thursday, July 16, 2015 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
Analyst Day
From:
Monday, April 13, 2015 9:00 am EDT (8:00 am CDT, 7:00 am MDT, 6:00 am PDT)
To:
Monday, April 13, 2015 12:00 pm EDT (11:00 am CDT, 10:00 am MDT, 9:00 am PDT)
Duration: 3 Hours
Related Materials:
Tenax Analyst Day Presentation (15.07 MB)
Business Review and Update in Conjuction with Filing of Fiscal Year 2015 Third Quarter Financial Report
From:
Wednesday, March 18, 2015 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Wednesday, March 18, 2015 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
Cowen and Company 35th Annual Health Care Conference
Corporate Update and Second Quarter Fiscal Year 2015 Financial Results Webcast
From:
Wednesday, December 17, 2014 8:30 am EST (7:30 am CST, 6:30 am MST, 5:30 am PST)
To:
Wednesday, December 17, 2014 9:30 am EST (8:30 am CST, 7:30 am MST, 6:30 am PST)
Duration: 1 Hour
Corporate Update and Discussion of First Quarter Fiscal Year 2015 Financial Results
From:
Wednesday, September 24, 2014 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Wednesday, September 24, 2014 9:30 am EDT (8:30 am CDT, 7:30 am MDT, 6:30 am PDT)
Duration: 1 Hour
Business Review and Update in Conjunction with Filing of Fiscal Year 2014 Annual Financial Report
From:
Tuesday, July 29, 2014 8:30 am EDT (7:30 am CDT, 6:30 am MDT, 5:30 am PDT)
To:
Tuesday, July 29, 2014 10:00 am EDT (9:00 am CDT, 8:00 am MDT, 7:00 am PDT)
Duration: 1 Hour, 30 Minutes
A conference call and live audio webcast to report financial results for the fourth quarter and fiscal year ended April 30, 2014, and provide a corporate update.
Oxygen Biotherapeutics, Inc. at Aegis Capital Healthcare Conference
Q3 2013 Oxygen Biotherapeutics, Inc. Earnings Conference Call 
Third Quarter 2016 Business Review and Update
Live Participant Dial In (Toll Free): 866-932-0173
Live Participant Dial In (International): 785-424-1630
Replay Number (Toll Free): 877-481-4010
Replay Number (International): 919-882-2331
Replay ID: 10145
Teleconference Replay Available Until: Nov 24, 2016 at 11:59 PM
Conference ID: TENAX

Fiscal Year 2016 Business Review and Update
Live Participant Dial In (Toll Free): (866) 682-6100
Live Participant Dial In (International): (862) 255-5401
Replay Number (Toll Free): 877-481-4010
Replay Number (International): 919-882-2331
Replay ID: 10286
Teleconference Replay Available Until: April 4, 2017 at 11:59 PM
Phase 2 Help Study Top Line Data
H. C. Wainwright ConferenceSeptember 16, 2020, 10:30am.
https://wsw.com/webcast/hcw7/tenx/1626951
Tenax Virtual R&D WebinarTenax Therapeutics will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST.
US/Canada Toll-Free Number: (833) 301-1155
US/Canada International Dial-In Number: (914) 987-7396
Conference ID 5783678
Acquisition of PH Precision Med Conference CallJanuary 21, 2021 @ 4:30pm
In addition, the conference call can be accessed by dialing (877) 405-1242 from the U.S. and (201) 389-0852 internationally, followed by the conference ID: 13715313.
An archived webinar recording of the event will be available on the website for approximately 30 days.
eHealth Radio Network InterviewGetting to know Tenax Therapeutics
Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)The webinar will feature a presentation by Key Opinion Leader (KOL) Daniel Burkhoff, M.D., Ph.D. (Cardiovascular Research Foundation) who will discuss the current treatment landscape and unmet medical need in treating patients with pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) and how Levosimendan could become an important new treatment option for this patient population. Dr. Burkhoff will be available to answer questions following the formal presentations.
Tenax's Chief Medical Officer, cardiologist Stuart Rich, M.D., will then discuss the clinical development plan for their novel therapy Levosimendan, a first-in-class K-ATP activator/ calcium sensitizer, as the first treatment for PH-HFpEF (WHO Group 2 Pulmonary Hypertension).
A live Q&A session will follow the formal presentations.
Watch the replay: https://media.rampard.com/20210816/
H.C. Wainwright 23rd Annual Global Investment ConferenceTenax Therapeutics will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
Webcast link to the presentation can be found here and will be available for up to 90 days after the conference.